Thromb Haemost 2021; 121(11): 1409-1416
DOI: 10.1055/s-0041-1726344
Coagulation and Fibrinolysis

Outcome of Surgical Interventions and Deliveries in Patients with Bleeding of Unknown Cause: An Observational Study

Caroline S. B. Veen
1   Department of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands
,
Elise J. Huisman
2   Department of Paediatric Haematology, Erasmus University Medical Centre–Sophia Children's Hospital, Rotterdam, The Netherlands
,
Lorenzo G. R. Romano
1   Department of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands
,
Celesta W. A. Schipaanboord
1   Department of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands
,
Marjon H. Cnossen
2   Department of Paediatric Haematology, Erasmus University Medical Centre–Sophia Children's Hospital, Rotterdam, The Netherlands
,
1   Department of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands
,
Frank W. G. Leebeek
1   Department of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands
,
Marieke J. H. A. Kruip
1   Department of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands
› Author Affiliations

Abstract

Background The most optimal management for patients with bleeding of unknown cause (BUC) is unknown, as limited data are available.

Objective Evaluate management and outcome of surgical procedures and deliveries in patients with BUC.

Materials and Methods All patients ≥12 years of age, referred to a tertiary center for a bleeding tendency, were included. Bleeding phenotype was assessed and hemostatic laboratory work-up was performed. Patients were diagnosed with BUC or an established bleeding disorder (BD). Data on bleeding and treatment during surgical procedures and delivery following diagnosis were collected.

Results Of 380 included patients, 228 (60%) were diagnosed with BUC and 152 (40%) with an established BD. In 14/72 (19%) surgical procedures major bleeding occurred and 14/41 (34%) deliveries were complicated by major postpartum hemorrhage (PPH). More specifically, 29/53 (55%) of the BUC patients who underwent surgery received prophylactic treatment to support hemostasis. Despite these precautions, 4/29 (14%) experienced major bleeding. Of BUC patients not treated prophylactically, bleeding occurred in 6/24 (25%). Of pregnant women with BUC, 2/26 (8%) received prophylactic treatment during delivery, one women with and 11 (46%) women without treatment developed major PPH.

Conclusion Bleeding complications are frequent in BUC patients, irrespective of pre- or perioperative hemostatic treatment. We recommend a low-threshold approach toward administration of hemostatic treatment in BUC patients, especially during delivery.

Author Contributions

C.S.B.V., E.J.H., M.H.C., F.W.G.L., and M.J.H.A.K. designed the study; C.S.B.V., E.J.H., L.G.R.R., and C.W.A.S. collected the data; C.S.B.V. and C.W.A.S. performed the statistical analyses; C.S.B.V., E.J.H., M.P.M.M., and M.J.H.A.K. interpreted the data; C.S.B.V. and M.J.H.A.K. wrote the manuscript. All authors critically revised the manuscript, agreed with its content, and approved for submission.


Supplementary Material



Publication History

Received: 10 October 2020

Accepted: 03 February 2021

Article published online:
14 April 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Quiroga T, Mezzano D. Is my patient a bleeder? A diagnostic framework for mild bleeding disorders. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 466-474
  • 2 Agren A, Wiman B, Stiller V. et al. Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis. J Thromb Haemost 2006; 4 (01) 201-208
  • 3 Podda GM, Bucciarelli P, Lussana F, Lecchi A, Cattaneo M. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost 2007; 5 (12) 2393-2398
  • 4 Quiroga T, Goycoolea M, Panes O. et al. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica 2007; 92 (03) 357-365
  • 5 Obaji S, Alikhan R, Rayment R, Carter P, Macartney N, Collins P. Unclassified bleeding disorders: outcome of haemostatic challenges following tranexamic acid and/or desmopressin. Haemophilia 2016; 22 (02) 285-291
  • 6 MacDonald S, Wright A, Beuche F. et al. Characterization of a large cohort of patients with unclassified bleeding disorder; clinical features, management of haemostatic challenges and use of global haemostatic assessment with proposed recommendations for diagnosis and treatment. Int J Lab Hematol 2020; 42 (02) 116-125
  • 7 Bowman M, Mundell G, Grabell J. et al. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost 2008; 6 (12) 2062-2066
  • 8 Elbatarny M, Mollah S, Grabell J. et al; Zimmerman Program Investigators. Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia 2014; 20 (06) 831-835
  • 9 Gebhart J, Hofer S, Panzer S. et al. High proportion of patients with bleeding of unknown cause in persons with a mild-to-moderate bleeding tendency: results from the Vienna Bleeding Biobank (VIBB). Haemophilia 2018; 24 (03) 405-413
  • 10 Hofer S, Ay C, Rejtö J. et al. Thrombin-generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause. J Thromb Haemost 2019; 17 (09) 1478-1488
  • 11 Leebeek FW, Eikenboom JC. Von Willebrand's disease. N Engl J Med 2016; 375 (21) 2067-2080
  • 12 Gresele P. Subcommittee on Platelet Physiology of the International Society on Thrombosis and Hemostasis. Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. J Thromb Haemost 2015; 13 (02) 314-322
  • 13 Mumford AD, Ackroyd S, Alikhan R. et al; BCSH Committee. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (03) 304-326
  • 14 Boender J, Kruip MJ, Leebeek FW. A diagnostic approach to mild bleeding disorders. J Thromb Haemost 2016; 14 (08) 1507-1516
  • 15 Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (11) 1935-1939
  • 16 Koshy M, Weiner SJ, Miller ST. et al; Cooperative Study of Sickle Cell Diseases. Surgery and anesthesia in sickle cell disease. Blood 1995; 86 (10) 3676-3684
  • 17 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
  • 18 Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8 (01) 202-204
  • 19 World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. 2012 ; Accessed February 24, 2021 at: http://apps.who.int/iris/bitstream/10665/75411/1/9789241548502_eng.pdf
  • 20 Pedersen AB, Mehnert F, Sorensen HT, Emmeluth C, Overgaard S, Johnsen SP. The risk of venous thromboembolism, myocardial infarction, stroke, major bleeding and death in patients undergoing total hip and knee replacement: a 15-year retrospective cohort study of routine clinical practice. Bone Joint J 2014; 96-B (04) 479-485
  • 21 Leonard DS, Fenton JE, Hone S. ABO blood type as a risk factor for secondary post-tonsillectomy haemorrhage. Int J Pediatr Otorhinolaryngol 2010; 74 (07) 729-732
  • 22 International Surgical Outcomes Study group. Global patient outcomes after elective surgery: prospective cohort study in 27 low-, middle- and high-income countries. Br J Anaesth 2016; 117 (05) 601-609
  • 23 Mauer AC, Khazanov NA, Levenkova N. et al. Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost 2011; 9 (01) 100-108
  • 24 Oberg AS, Hernandez-Diaz S, Palmsten K, Almqvist C, Bateman BT. Patterns of recurrence of postpartum hemorrhage in a large population-based cohort. Am J Obstet Gynecol 2014; 210 (03) 229.e1-229.e8
  • 25 Buzaglo N, Harlev A, Sergienko R, Sheiner E. Risk factors for early postpartum hemorrhage (PPH) in the first vaginal delivery, and obstetrical outcomes in subsequent pregnancy. J Matern Fetal Neonatal Med 2015; 28 (08) 932-937
  • 26 Stoof SC, van Steenbergen HW, Zwagemaker A. et al. Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey. Haemophilia 2015; 21 (04) 505-512
  • 27 Prick BW, Auf Altenstadt JF, Hukkelhoven CW. et al. Regional differences in severe postpartum hemorrhage: a nationwide comparative study of 1.6 million deliveries. BMC Pregnancy Childbirth 2015; 15: 43
  • 28 WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 389 (10084): 2105-2116
  • 29 Stoof SC, Cnossen MH, de Maat MP, Leebeek FW, Kruip MJ. Side effects of desmopressin in patients with bleeding disorders. Haemophilia 2016; 22 (01) 39-45
  • 30 Crescenzi G, Landoni G, Biondi-Zoccai G. et al. Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. Anesthesiology 2008; 109 (06) 1063-1076
  • 31 Shakur H, Roberts I, Bautista R. et al; CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376 (9734): 23-32
  • 32 Rodeghiero F, Pabinger I, Ragni M. et al. Fundamentals for a systematic approach to mild and moderate inherited bleeding disorders: an EHA consensus report. HemaSphere 2019; 3 (04) e286
  • 33 Federici AB, Bucciarelli P, Castaman G. et al. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood 2014; 123 (26) 4037-4044
  • 34 Orsini S, Noris P, Bury L. et al; European Hematology Association - Scientific Working Group (EHA-SWG) on thrombocytopenias and platelet function disorders. Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. Haematologica 2017; 102 (07) 1192-1203
  • 35 Relke N, Kuthiala S, Grabell J, Hopman WM, James P. The bleeding score: useful in predicting spontaneous bleeding events in adults with bleeding of unknown cause?. Haemophilia 2020; 26 (02) e31-e33